BPC-157 — Body Protection Compound 157 — is a synthetic 15-amino-acid peptide fragment derived from a larger gastric protective protein originally isolated from human gastric juice in the 1990s. In animal studies it shows a startlingly broad profile: accelerated healing of tendon, ligament, muscle, skin, gut, blood vessel, and nerve injuries; anti-inflammatory and gut-protective effects; and no detectable toxicity across the tested dose ranges. In human subjects, there is almost no data. In the wellness and athletic underground, it is one of the most popular research chemicals being used off-label, primarily by injection, for musculoskeletal injury recovery. The gap between what the rat literature suggests and what we can say about humans is enormous, and that gap is the entire honest story here.
At a glance
What it does
Virtually every claim about BPC-157's effects in humans is extrapolated from preclinical (mostly rat) data. In rodent models, BPC-157 accelerates healing of experimentally induced tendon transection injuries, muscle crush injuries, ligament sprain, skin wounds, gastric ulcers, colitis, liver injury, and various peripheral nerve injuries. It appears to modulate the vascular response to injury, promoting angiogenesis at the wound site and stabilizing endothelial function. It also appears to modulate dopamine, serotonin, and GABA signaling in some models, which is the basis of secondary claims about mood and cognition.
The mechanism proposed across studies involves upregulation of growth factor receptors (particularly VEGFR2), activation of the nitric oxide system, modulation of FAK-paxillin signaling in cell motility, and effects on gut microbiome composition. Whether the mechanism is unified or BPC-157 hits many pathways with modest potency at each is not settled. Some of the reported effects are likely genuinely pleiotropic; some may be artifacts of high local concentrations in small animal models that do not translate.
Users in the gray market primarily take it for soft-tissue injuries — tendinopathy, ligament sprains, chronic joint pain, postoperative recovery — with anecdotal reports of faster-than-expected resolution. Secondary off-label uses include gastrointestinal inflammation and occasionally mood. The subjective reports are consistent enough across users that something is probably happening; whether that something is the drug or placebo or regression to the mean from the injury natural history, no one can say from the available data.
How it works
In rat tendon healing models, BPC-157 appears to accelerate recovery partly by enhancing angiogenesis at the injury site. Fresh blood vessel formation is the rate-limiting step for tissue repair, and BPC-157 upregulates VEGFR2 expression and promotes endothelial cell migration and tube formation in vitro. This vascular effect would, if it translates, plausibly accelerate a range of soft-tissue recoveries.
Gut-protective effects are thought to involve nitric oxide system activation, maintenance of gastric mucosal integrity, and modulation of the gut-brain axis. BPC-157 was originally discovered and characterized in the context of protecting against experimentally induced gastric ulcers from NSAIDs, alcohol, and stress — it is a gastric protective peptide first, and the musculoskeletal and neurological effects were discovered later.
Routes of administration in research include intraperitoneal and oral (the latter remarkable because most peptides are degraded in the gut; BPC-157 is reportedly stable in gastric juice, consistent with its origin as a gastric protein fragment). Users typically self-inject subcutaneously near the injury site, or less commonly intramuscularly or systemically, based on the theory that local delivery maximizes local effect. There is essentially no human pharmacokinetic data to guide these choices.
Levels & ranges
There is no clinical "level" of BPC-157. It is not an endogenous human compound; it is a synthetic fragment of a larger gastric protein. No validated human reference range exists because no regulated clinical trials have characterized it.
Typical gray-market dosing is 200-500 micrograms per day by subcutaneous injection, sometimes split into two doses, for 2-6 week cycles around an injury or surgical recovery. Oral dosing in supplements and compounded products ranges from 250 micrograms to a few milligrams; absorption is uncertain but animal data suggest some oral bioavailability is possible. These protocols are based on extrapolation from animal dose-response data (which used doses much higher on a mg/kg basis than typical human use) and observational anecdote, not clinical trial evidence.
Products sold online in vials labeled "for research use only, not for human consumption" often have variable actual content. Independent mass spectrometry testing of commercial BPC-157 products has found a substantial percentage contain less than labeled peptide, contain degraded product, or are not BPC-157 at all. This supply-side reality is a real part of the safety profile — you cannot separate "is BPC-157 safe in humans" from "is what I just injected actually BPC-157."
When it goes wrong
There are no well-documented serious adverse events in the published case literature, which sounds reassuring but reflects the absence of systematic human trials rather than evidence of safety. Anecdotal reports describe injection-site reactions, mild headaches, flushing, and rarely unusual sensations reported by users. Rare case reports of acute issues in users of compounded peptides — hypersensitivity reactions, contamination from impurity, etc. — are in the literature but difficult to attribute specifically.
Theoretical concerns deserve attention. BPC-157 promotes angiogenesis; angiogenesis is also a feature of tumor growth. Whether administration at typical gray-market doses meaningfully elevates cancer risk, or whether this is a theoretical concern only, is unknown — the timeline of systematic observation is too short and the population too uncontrolled. Anyone with known malignancy should not use it outside a formal clinical trial. Similarly, the peptide's effects on growth factor signaling raise theoretical concerns for patients with proliferative vascular diseases (retinopathy, certain macular degeneration) but no data exists either way.
Legally and practically, BPC-157 is not approved by the FDA or any comparable regulator for human use. In the US, the FDA explicitly flagged BPC-157 in 2023 as not eligible for inclusion in compounded drugs under Section 503A due to lack of sufficient clinical data — which is why many compounding pharmacies stopped offering it. Users are on their own for sourcing, dose, and technique, and legal status varies by jurisdiction.
Interactions
Known interactions with other drugs are unstudied. In animal models, BPC-157 attenuates NSAID-induced gastric ulceration and protects against the gut toxicity of other medications; this is one of the few areas where its mechanism is specifically characterized. Theoretical interactions with anticoagulants, antiplatelet drugs, and other angiogenesis modulators are plausible but unstudied in humans.
Combined peptide stacks — BPC-157 with TB-500 (another regenerative peptide), with growth hormone secretagogues, with IGF-1, etc. — are common in gray-market use, and the interaction profile of those stacks is entirely unknown. The experimental approach taken by individual users is essentially n=1 self-experimentation with compounds of variable purity and no independent monitoring.
Healing is not a neutral process. Accelerating tissue repair without addressing the cause of the injury — overtraining, biomechanical issues, undertreated inflammation — can lead to re-injury at a remodeled but still imperfect site. Peptides cannot compensate for poor rehabilitation protocols, inadequate sleep, or chronic overload.
Honest take
The rat data on BPC-157 is unusually consistent and mechanistically plausible; the human data is essentially nonexistent. Users report positive effects often enough that something is probably going on, but we do not know whether that something is the drug, placebo, or natural injury resolution. The supply chain is unregulated and a substantial fraction of what is sold contains less peptide than labeled or contains contamination. The long-term safety picture is unknown, and the theoretical angiogenesis concern is real enough that anyone with malignancy history should stay away. For the specific case of a stubborn soft-tissue injury that has not responded to conservative management, where conventional alternatives are limited, some experienced users conclude the risk-benefit is acceptable — but that is an individual research-chemical decision made with full awareness of unknowns, not a therapy. The honest answer to "does BPC-157 work?" is that the rat data is impressive and we genuinely do not know if it translates.
Sources
- Sikiric et al., Current Pharmaceutical Design (2018) — the comprehensive review of BPC-157 preclinical literature from the original research group.
- Chang et al., Journal of Orthopaedic Research — on tendon healing effects in rat models and proposed vascular mechanisms.
- Huang et al., European Journal of Pharmacology — on angiogenesis mechanisms and VEGFR2 upregulation.
- FDA 503A List update (2023) — the regulatory statement flagging BPC-157 as ineligible for pharmacy compounding due to insufficient clinical data.